• Je něco špatně v tomto záznamu ?

Invasive fungal diseases impact on outcome of childhood ALL - an analysis of the international trial AIEOP-BFM ALL 2009

T. Lehrnbecher, AH. Groll, S. Cesaro, J. Alten, A. Attarbaschi, D. Barbaric, N. Bodmer, V. Conter, S. Izraeli, G. Mann, A. Möricke, F. Niggli, M. Schrappe, J. Stary, E. Zapotocka, M. Zimmermann, S. Elitzur

. 2023 ; 37 (1) : 72-78. [pub] 20221212

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004741
E-zdroje Online Plný text

NLK ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Nursing & Allied Health Database (ProQuest) od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 36509893
DOI 10.1038/s41375-022-01768-x
Knihovny.cz E-zdroje

In children with acute lymphoblastic leukemia (ALL), risk groups for invasive fungal disease (IFD) with need for antifungal prophylaxis are not well characterized, and with the advent of new antifungal compounds, current data on outcome are scarce. Prospectively captured serious adverse event reports of children enrolled in the international, multi-center clinical trial AIEOP-BFM ALL2009 were screened for proven/probable IFD, defined according to the updated EORTC/MSG consensus definitions. In a total of 6136 children (median age 5.2 years), 224 proven/probable IFDs (65 yeast and 159 mold) were reported. By logistic regression, the risk for proven/probable IFDs was significantly increased in children ≥12 years and those with a blast count ≥10% in the bone marrow on day 15 (P < 0.0001 each). Proven/probable IFDs had a 6-week and 12-week mortality of 10.7% and 11.2%, respectively. In the multivariate analysis, the hazard ratio for event-free and overall survival was significantly increased for proven/probable IFD, age ≥12 years, and insufficient response to therapy (P < 0.001, each). Our data define older children with ALL and those with insufficient treatment-response at high risk for IFD. As we show that IFD is an independent risk factor for event-free and overall survival, these patients may benefit from targeted antifungal prophylaxis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004741
003      
CZ-PrNML
005      
20230425171709.0
007      
ta
008      
230418s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41375-022-01768-x $2 doi
035    __
$a (PubMed)36509893
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Lehrnbecher, Thomas $u Pediatric Hematology and Oncology, Hospital for Children and Adolescents, Johann Wolfgang Goethe-University, Frankfurt, Germany. Thomas.Lehrnbecher@kgu.de $1 https://orcid.org/0000000260223439 $7 xx0073376
245    10
$a Invasive fungal diseases impact on outcome of childhood ALL - an analysis of the international trial AIEOP-BFM ALL 2009 / $c T. Lehrnbecher, AH. Groll, S. Cesaro, J. Alten, A. Attarbaschi, D. Barbaric, N. Bodmer, V. Conter, S. Izraeli, G. Mann, A. Möricke, F. Niggli, M. Schrappe, J. Stary, E. Zapotocka, M. Zimmermann, S. Elitzur
520    9_
$a In children with acute lymphoblastic leukemia (ALL), risk groups for invasive fungal disease (IFD) with need for antifungal prophylaxis are not well characterized, and with the advent of new antifungal compounds, current data on outcome are scarce. Prospectively captured serious adverse event reports of children enrolled in the international, multi-center clinical trial AIEOP-BFM ALL2009 were screened for proven/probable IFD, defined according to the updated EORTC/MSG consensus definitions. In a total of 6136 children (median age 5.2 years), 224 proven/probable IFDs (65 yeast and 159 mold) were reported. By logistic regression, the risk for proven/probable IFDs was significantly increased in children ≥12 years and those with a blast count ≥10% in the bone marrow on day 15 (P < 0.0001 each). Proven/probable IFDs had a 6-week and 12-week mortality of 10.7% and 11.2%, respectively. In the multivariate analysis, the hazard ratio for event-free and overall survival was significantly increased for proven/probable IFD, age ≥12 years, and insufficient response to therapy (P < 0.001, each). Our data define older children with ALL and those with insufficient treatment-response at high risk for IFD. As we show that IFD is an independent risk factor for event-free and overall survival, these patients may benefit from targeted antifungal prophylaxis.
650    _2
$a mladiství $7 D000293
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a lidé $7 D006801
650    _2
$a antifungální látky $x terapeutické užití $7 D000935
650    12
$a mykózy $x farmakoterapie $x etiologie $7 D009181
650    12
$a akutní lymfatická leukemie $x komplikace $x farmakoterapie $7 D054198
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rizikové faktory $7 D012307
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Groll, Andreas H $u Infectious Disease Research Program, Department of Pediatric Hematology and Oncology and Center for Bone Marrow Transplantation, University Children's Hospital Münster, Münster, Germany $1 https://orcid.org/000000031188393X
700    1_
$a Cesaro, Simone $u Paediatric Haematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy $1 https://orcid.org/0000000286989547
700    1_
$a Alten, Julia $u Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
700    1_
$a Attarbaschi, Andishe $u St. Anna Kinderspital and Children's Cancer Research Institute, Vienna, Austria
700    1_
$a Barbaric, Draga $u Sydney Children's Hospital, Randwick, NSW, Australia
700    1_
$a Bodmer, Nicole $u University Children's Hospital Zurich, Zurich, Switzerland
700    1_
$a Conter, Valentino $u Clinica Pediatrica and Centro Ricerca Tettamanti, Università di Milano-Bicocca, Fondazione MBBM/S.Gerardo Hospital, Monza, Italy
700    1_
$a Izraeli, Shai $u Pediatric Hematology-Oncology, Schneider Children's Medical Center, Petah Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel $1 https://orcid.org/0000000269382540
700    1_
$a Mann, Georg $u St. Anna Kinderspital and Children's Cancer Research Institute, Vienna, Austria
700    1_
$a Möricke, Anja $u Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
700    1_
$a Niggli, Felix $u University Children's Hospital Zurich, Zurich, Switzerland
700    1_
$a Schrappe, Martin $u Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
700    1_
$a Stary, Jan $u Czech Working Group for Pediatric Hematology, Prague, Czech Republic
700    1_
$a Zapotocka, Ester $u Department of Pediatric Hematology/Oncology, University Hospital Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Zimmermann, Martin $u Department of Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany
700    1_
$a Elitzur, Sarah $u Pediatric Hematology-Oncology, Schneider Children's Medical Center, Petah Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel $1 https://orcid.org/0000000234957578
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 37, č. 1 (2023), s. 72-78
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36509893 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171705 $b ABA008
999    __
$a ok $b bmc $g 1925061 $s 1190950
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 37 $c 1 $d 72-78 $e 20221212 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace